-       Report 
- September 2025
-  150 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- October 2025
-  195 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- September 2025
-  150 Pages 
- United States 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- September 2025
-  150 Pages 
- Middle East 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- February 2024
-  115 Pages 
- Global 
   From       €4249EUR$4,750USD£3,737GBP 
           -       Report 
- May 2024
-  182 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
             The Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) market is a subset of the pharmaceutical intermediates industry. It is composed of companies that specialize in the development and manufacturing of APIs for pharmaceutical products. These companies provide services such as process development, analytical development, and manufacturing of APIs. They also provide support services such as regulatory affairs, quality assurance, and supply chain    management.
The API CDMO market is highly competitive, with companies offering a wide range of services and capabilities. Companies in the market are typically large, multinational organizations with extensive experience in the pharmaceutical industry.
Some of the major companies in the API CDMO market include Lonza, Boehringer Ingelheim, Patheon, Cambrex, and Evonik. Show Less   Read more